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Glutathione is a thiol-disulfide exchange peptide critical for
buffering oxidative or chemical stress, and an essential cofactor
in several biosynthesis and detoxification pathways. The ratelimiting step in its de novo biosynthesis is catalyzed by glutamate
cysteine ligase, a broadly expressed enzyme for which limited
structural information is available in higher eukaryotic species.
Structural data are critical to the understanding of clinical glutathione deficiency, as well as rational design of enzyme modulators that could impact human disease progression. Here, we
have determined the structures of Saccharomyces cerevisiae glutamate cysteine ligase (ScGCL) in the presence of glutamate and
MgCl2 (2.1 Å; R ⴝ 18.2%, Rfree ⴝ 21.9%), and in complex with
glutamate, MgCl2, and ADP (2.7 Å; R ⴝ 19.0%, Rfree ⴝ 24.2%).
Inspection of these structures reveals an unusual binding pocket
for the ␣-carboxylate of the glutamate substrate and an ATPindependent Mg2ⴙ coordination site, clarifying the Mg2ⴙ
dependence of the enzymatic reaction. The ScGCL structures
were further used to generate a credible homology model of the
catalytic subunit of human glutamate cysteine ligase (hGCLC).
Examination of the hGCLC model suggests that post-translational modifications of cysteine residues may be involved in the
regulation of enzymatic activity, and elucidates the molecular
basis of glutathione deficiency associated with patient hGCLC
mutations.

Glutathione, ␥-glutamylcysteinyl glycine, is a low molecular
weight thiol, central to maintenance of redox homeostasis.
Among its normal functions are the scavenging of reactive oxygen and nitrogen species (1), storage and transport of cysteine
(2, 3), leukotriene, and prostaglandin biosynthesis (4, 5), and
regulation of enzyme activity via reduction of disulfide bonds
and glutathionylation (6, 7). Disruption of glutathione metabolism is associated with the progression of AIDS, cancer, and
neurodegenerative conditions such as Parkinson and Alzheimer disease (8 –12). Polymorphisms that reduce activity of glu-
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tamate cysteine ligase (GCL),2 the first and rate-limiting
enzyme in de novo synthesis of glutathione, are correlated with
reduced glutathione levels in patients with hemolytic anemia,
schizophrenia and other neurological disorders (13–16). Given
its importance both in normal and disease states, there is considerable interest in the development of novel compounds that
could be used to modulate intracellular glutathione levels,
potentially via GCL.
Glutathione is synthesized from its three constituent amino
acids by consecutive action of two cytosolic ATP-dependent
enzymes: GCL and glutathione synthetase (17). GCL catalyzes
the conjugation of the ␥-carboxyl group of L-glutamate to the
amino group of L-cysteine (17). The proposed catalytic mechanism proceeds via phosphorylation of the ␥-carboxylate of
L-glutamate by ATP (18 –20). The ␣-amino group of L-cysteine
acts as a nucleophile, attacking the ␥-glutamyl phosphate intermediate to produce ␥-glutamylcysteine. This dipeptide is then
coupled in an analogous fashion to glycine by glutathione synthetase to generate glutathione. As the committed step of glutathione biosynthesis, GCL activity is regulated by L-cysteine
availability (21), feedback inhibition by glutathione (22), and
transcriptional and post-translational regulation (23).
Based on sequence analysis, three distinct groups of GCL
have been identified. Groups 1 and 3 are comprised of bacterial
and plant orthologues (24). Recently, x-ray crystal structures of
Escherichia coli (Group 1) (25) and Brassica juncea (Group 3)
(26) GCL were described, providing the first structural insights
into ␥-glutamylcysteine synthesis. However, low sequence
identity (⬍10%) between enzymes of different groups has precluded translation of these structural data into a detailed understanding of the molecular features of enzymes in Group 2, the
class that encompasses yeast and mammalian GCL. One structurally unique feature of several Group 2 GCL is the potential
for higher order regulation imposed by their existence in
reversible heterodimeric complexes of a catalytic (GCLC)
and a modulatory subunit (GCLM) (17). To circumvent the
inherent challenges associated with structural studies of the
complex, we selected the monomeric Saccharomyces cerevisiae GCL (ScGCL), a member of a unique subclass of Group
2 GCL, as a model system for higher eukaryotic GCL.
Although ScGCL differs from human GCLC in its oligomeric
state, the two enzymes share ⬃45% sequence identity (24).
2

The abbreviations used are: GCL, glutamate cysteine ligase; DTT, dithiothreitol; r.m.s.d., root mean-square deviation; AMP-PNP, adenosine 5⬘-(␤,␥-imido)triphosphate; PDB, Protein Data Bank; MES, 2-(N-morpholino)ethanesulfonic acid; PEG, polyethyleneglycol.
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Structure of Glutamate Cysteine Ligase
In the current study, we present the crystal structures of
ScGCL in complex with glutamate and Mg2⫹, as well as in the
presence of glutamate, Mg2⫹, and ADP. Examination of these
structures provides considerable insights into catalysis and
reveals a unique coordination at the ␣-carboxylate of the glutamate substrate. Based on the ScGCL structure, a homology
model of human GCLC was generated to investigate the molecular details of several human patient mutations with reduced
activity, and to aid in the design of novel modulators of GCL
activity.

EXPERIMENTAL PROCEDURES
Generation of ScGCL Expression Construct—A predicted
open reading frame in the S. cerevisiae genome (KEGG Data
Base Entry YJL101C) (27, 28) was amplified by the polymerase
chain reaction using S. cerevisiae genomic DNA (American
Type Culture Collection) as a template. Designed primers contained SpeI (forward) and SalI (reverse) restrictions sites. The
resultant 2-kb product was digested with the relevant enzymes
and ligated into a complementarily digested pET-21a(⫹)
expression vector (Novagen; NheI and SalI), thus incorporating
a C-terminal histidine tag. The expression construct was
sequenced at the Genomics Facility of University of Nebraska
(Lincoln, NE) and confirmed to be identical to the YJL101C
sequence.
Protein Expression and Purification—The ScGCL construct
was used to transform Escherichia coli RosettaTM2(DE3) pLysS
cells (Novagen). Cells were grown in 2xYT medium containing
100 g ml⫺1 ampicillin and 34 g ml⫺1 chloramphenicol at
37 °C, and ScGCL production was induced by the addition of
500 M isopropyl-1-thio-␤-D-galactopyranoside once the cells
reached an A600 of 0.6. After induction, cultures were grown for
4 h at 30 °C. Cells were harvested by centrifugation (20 min,
8000 ⫻ g, 4 °C) and stored at ⫺80 °C. Frozen cell pellets were
thawed, resuspended in lysis buffer (50 mM sodium phosphate
buffer, pH 8.0, 300 mM NaCl, 0.2 mM protease inhibitor, 10 mM
imidazole), and disrupted by sonication. Following centrifugation to remove cellular debris (30 min, 20,000 ⫻ g, 4 °C), the
supernatant was loaded onto a HisTrap Chelating HP Column
(GE Healthcare) equilibrated with lysis buffer. The column was
washed to baseline (A280), and the remaining bound proteins
were eluted using a linear imidazole gradient (10 –250 mM).
Fractions containing ScGCL were pooled, concentrated, and
loaded onto a Sephacryl 200 gel filtration column (16 ⫻ 600
mm) equilibrated with 50 mM Tris-HCl, pH 7.4, 300 mM
NaCl, and 2 mM DTT. Samples containing ScGCL were
pooled and dialyzed against crystallization buffer (20 mM
Tris-HCl, pH 7.4, 2 mM DTT). The enzyme was concentrated
to 12 mg ml⫺1 using an Amicon ultrafiltration device
(Stirred cell 8050, 10-kDa cutoff), flash-frozen in liquid
nitrogen, and stored at ⫺80 °C. The enzyme concentration
was determined by absorbance (280 nm) using a calculated
extinction coefficient (29) of 105,200 M⫺1 cm⫺1.
Characterization of ScGCL—ScGCL was examined by analytical gel filtration chromatography on a Superdex 200 HR
10/30 column (GE Healthcare, equilibrated with 20 mM Tris,
pH 7.4, 150 mM NaCl, 2 mM DTT). Molecular weight determinations were made by comparison with the following standNOVEMBER 20, 2009 • VOLUME 284 • NUMBER 47

ards: thyroglobulin, 699 kDa; ferritin, 416 kDa; catalase, 219
kDa; aldolase, 176 kDa; albumin, 67 kDa; ovalbumin, 47 kDa;
chymotrypsinogen A, 20 kDa; RNase A, 15 kDa (GE Healthcare). Enzymatic activity was measured in the presence of 20
mM L-glutamate, 10 mM L-cysteine, 5 mM ATP, and 50 mM
MgCl2, using an indirect assay that couples ADP production to
NADH oxidation (30).
Structure Determination of ScGCL—Initial crystallization
screening was performed by the sitting-drop vapor-diffusion
method using sparse matrix crystal screens (Qiagen). Crystals
of ScGCL (7 mg/ml) were ultimately grown at 18 °C out of a
solution of 12% (w/v) PEG 400, 100 mM MES, pH 6.8, and
reached the dimensions 0.15 ⫻ 0.15 ⫻ 0.15 mm. Once suitable
crystallization conditions were established, several complexes
were co-crystallized as indicated below.
An extensive search of potential heavy metal derivatives was
conducted and a derivative suitable for phasing was identified.
ScGCL was incubated with 1 mM trimethyl lead acetate, 5 mM
L-glutamate, 5 mM ATP, and 20 mM MgCl2 and co-crystallized.
Crystals were transferred into an appropriate stabilizing solution, containing 100 mM MES, pH 6.8, 5 mM ATP, 5 mM L-glutamate, 20 mM MgCl2, and 30% PEG 400 and vitrified in the
cryostream (X-Stream cooling system; Rigaku) (31). Diffraction
data were collected using radiation produced by a Rigaku
MicroMax-007 x-ray generator fitted with confocal blue optics
and an R-axis IV⫹⫹ image plate system ( ⫽ 1.54 Å; 100 K).
Data were processed with the HKL2000 software package (32).
The structure of ScGCL derivatized with trimethyl lead acetate was solved using experimental phases determined by
single wavelength anomalous diffraction utilizing the PHENIX
software suite (33). A readily interpretable electron density map
was obtained, and automated model building was employed.
The initial model contained a single Pb2⫹ bound at the enzyme
active site. Since the Pb2⫹ occupied one of the three Mg2⫹
binding sites, M2 (see below), this initial model was used only as
a search probe for subsequent ScGCL complex structure
determinations.
To examine the structural basis of catalysis and substrate
recognition, several ScGCL complexes were pursued. ScGCL
was incubated with 5 mM L-glutamate, 5 mM AMP-PNP, 5 mM
L-cysteine, and 20 mM MgCl2 or 5 mM L-glutamate, 5 mM ADP,
5 mM L-cysteine, and 20 mM MgCl2 and both complexes were
crystallized. Crystals were transferred to a suitable cryosolution
(30% PEG 400, 100 mM MES, pH 6.8, and the appropriate
ligands) and then stored in liquid nitrogen. Diffraction data
( ⫽ 0.9 Å; 100 K) were collected on Beamline 14-BM-C of
BioCARS at Argonne National Laboratory’s Advanced Photon
Source and were processed with the HKL2000 software package (32).
The structures were solved by molecular replacement within
the PHENIX software suite (33) using the initial ScGCL model
as a probe. Iterative rounds of model building and refinement
were carried out using Coot (34) and Refmac5 (35) respectively.
As the protein models neared completion, water molecules
obeying proper hydrogen-bonding constraints with electron
density greater than 1.0  on a 2Fo–Fc map and 4.0  on an
Fo–Fc map were also included in the final structure. Model
geometry was monitored using MOLPROBITY (36), and figJOURNAL OF BIOLOGICAL CHEMISTRY
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TABLE 1
Data collection and refinement statistics
Data collection
PDB Accession Code

Temperature (K)
Space group
Cell dimensions
a, b, c (Å)
Resolution (Å)
Rmerge (%)
Mean I/I
Completeness (%)
Redundancy

Glu/ADP/Mg2ⴙ/Pb

Glu/Mg2ⴙ

Glu/ADP/Mg2ⴙ

Glu/ADP/Mn2ⴙ

NA
1.54Å
100
P43212

3IG5
0.90 Å
100
P43212

3IG8
0.90 Å
100
P43212

NA
1.54Å
100
P43212

117.7, 117.7, 165.7
50-2.3 (2.38-2.30)a
8.4 (63.7)
40.2 ( 3.9)
99.9 (100)
17.4 (16.1)

117.4, 117.4, 165.4
50-2.1 (2.18-2.10)
6.9 (57.8)
20.9 (1.8)
97.5 (96.1)
4.5 (3.6)

117.8, 117.8, 165.4
50-2.7 (2.75-2.70)
9.6 (72.7)
19.4 (2.3)
94.7 (96.0)
7.0 (5.8)

117.7, 117.7, 165.7
50-2.9 (2.95-2.90)
11.3 (71.5)
12.1 (1.8)
99.6 (99.7)
5.5 (5.3)

32-2.1 (2.15-2.10)
54225
18.2/21.9 (26.2/29.8)
5869
5490
51
328
38.0
37.7
54.1
39.7

34-2.7 (2.76-2.70)
27023
19.0/24.2 (22.8/29.7)
5621
5461
50
110
43.2
43.4
51.5
36.9

Refinement
Resolution (Å)
No. reflections
Rwork/Rfree (%)
No. atoms
Protein
Ligand/ion
Water
Average B-factors (Å2)
Protein
Ligand/ion
Water
R.m.s. deviations from ideal
Bond lengths (Å)
Bond angles (°)
Ramachandran statistics
Favored
Allowed
a

0.019
1.68
96.7%
99.7%

0.019
1.88
94.0%
99.0%

Values in parentheses are for highest-resolution shell.

ures were produced using Chimera (37). To validate the location of the metal binding sites, ScGCL was crystallized in the
presence of 5 mM L-glutamate, 5 mM ADP, 5 mM L-cysteine, and
20 mM MnCl2. Diffraction data were collected using radiation
produced by a Rigaku MicroMax-007 x-ray generator fitted
with confocal blue optics and an R-axis IV⫹⫹ image plate system ( ⫽ 1.54 Å; 100 K). Data were processed with the
HKL2000 software package (32) and an anomalous difference
map was calculated.

RESULTS
Characterization of ScGCL—ScGCL was purified from E. coli
with a specific activity of ⬃10 moles/min/mg of protein, comparable to other glutamate cysteine ligases. Both analytical gel
filtration chromatography as well as sedimentation velocity
experiments indicated that ScGCL was likely a monomer in
solution (data not shown). As discussed below, a single
polypeptide chain is contained within the asymmetric unit of
ScGCL crystals, and relatively modest interactions between
crystallographically related molecules are observed, consistent
with a monomeric enzyme. Although GCL is typically a heterodimer comprised of a catalytic subunit and a modifier subunit in higher eukaryotes (Group 2), phylogenetic analysis suggests that members of the hemiascomycete class of fungi do not
have a modifier subunit and that ScGCL likely functions as a
monomer in vivo.
Overall Structure of ScGCL—Phase information was obtained using single wavelength anomalous diffraction data collected from a crystal of ScGCL derivatized with trimethyl lead
acetate (Table 1). The PHENIX software suite (33) was used to
identify the positions of one lead (coincident with the M2 bind-
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ing site described below) and each of the ordered 22 sulfur
atoms in the final model (8 of 9 cysteine residues; 14 of 15
methionine residues), and to calculate an initial experimentally
phased map. ScGCL crystals have a calculated solvent content
of ⬃65% and density modification in PHENIX significantly
improved the experimental phases (supplemental Fig. S1).
Automated chain tracing resulted in a model that contained
⬃90% of the ScGCL sequence. This initial model was used for
subsequent structure determinations of the ScGCL complexes
by molecular replacement. ScGCL was also crystallized in the
presence of L-glutamate, AMP-PNP, cysteine, and Mg2⫹, or
2⫹
L-glutamate, ADP, cysteine, and Mg . Data sets were collected
to 2.1 Å and 2.7 Å, respectively (Table 1). However, convincing
electron density was not observed for either AMP-PNP or cysteine. Refinement statistics for the final ScGCL models, corresponding to residues 2 through 676, are provided in Table 1.
The ScGCL/Glu/Mg2⫹ and the ScGCL/Glu/Mg2⫹/ADP complexes have 99.7 and 99.0% of residues, respectively, in the
allowed region of the Ramachandran plot as assessed by MOLPROBITY (36).
A single polypeptide chain is contained within the asymmetric unit of ScGCL crystals, and relatively modest interactions
between crystallographically related molecules are observed,
consistent with a monomeric enzyme. The ScGCL fold (Fig. 1)
shows strong structural similarity to other members of the
ATP-grasp superfamily, and has a core ␤-sheet comprised of six
anti-parallel ␤-strands surrounded by ␣-helices. The N terminus of the protein defines a lip of the active site, which is situated in a central cavity of the protein. Despite low sequence
identity (⬃10%), the core fold of the ScGCL structure is similar
VOLUME 284 • NUMBER 47 • NOVEMBER 20, 2009
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FIGURE 1. Ribbon representation of the recombinant ScGCL crystal structure. A functionally active ScGCL monomer (⬃78 kDa) is contained in the
asymmetric unit (center). The core ␤-sheet is colored in yellow, ␣-helical elements in green, and loop regions in gray. The glutamate substrate is shown in ball
and stick representation with carbon atoms colored in gray, oxygen atoms in red, and nitrogen atoms in blue. A bound Mg2⫹ is represented by a purple sphere,
and the N- and C-terminal residues are indicated. For comparison, the ribbon representations of the previously determined E. coli (25) (2D32) and B. juncea (26)
(2GWD) GCL structures are shown with ␤-strands colored in yellow, ␣-helices in blue, and loop regions in gray.

to those of the previously determined E. coli (25) (2D32; rmsd
2.3 Å for 266 C␣ atoms) and B. juncea (26) (2GWD; r.m.s.d. 2.0
Å for 321 C␣ atoms) GCL structures with several differences of
note (Fig. 1). The larger ScGCL structure (678 residues), relative to the bacterial (518 residues) and plant (514 residues)
homologues, contains three additional short ␤-sheets formed
by anti-parallel ␤-strands, as well as extended ␣-helical and
loop regions.
An intriguing feature of the structure is a cysteine residue,
Cys-70, that appears to be oxidized to sulfenic acid (supplemental Fig. S2). As discussed below, there are several prominent cysteine residues in ScGCL, suggesting that cysteine
oxidation and/or additional post-translational modifications may play an important regulatory role. In support of
this hypothesis, previous studies have shown that H2O2
increases the enzymatic activity of GCL (38, 39). However,
the mechanism of this activation was not demonstrated, and
additional studies are needed to clarify the functional significance of Cys-70 oxidation.
Identification of the L-glutamate Binding Site and an ATPindependent Bound Mg2⫹ Cofactor—In the ScGCL structure,
L-glutamate is bound in the extended conformation in the interior of the funnel-shaped active site cavity (Fig. 2A), with the
side chains of Arg-313 and Tyr-362 positioning the ␣-carboxylate of the glutamate substrate. The ␣-amino group of
glutamate is within hydrogen bond distance of the backbone
carbonyl of Cys-264, the ␥-carboxylate of Glu-52, and a
bound water molecule, which is positioned by the carboxylate of Glu-96 and the backbone carbonyl of Met-262. The
␥-carboxylate of the glutamate substrate occupies one of the
coordination sites of an interesting Mg2⫹ cofactor (discussed below) and is in close proximity to the side chain of
Arg-472. An additional feature of the glutamate-binding
pocket is Cys-266, which is stacked 3.2 Å below the ␣-carboxylate carbon atom.
NOVEMBER 20, 2009 • VOLUME 284 • NUMBER 47

Interestingly, despite the absence of ATP, electron density
was also observed for an octahedrally coordinated Mg2⫹ at the
enzyme active site. The bound Mg2⫹ is within 2.2 Å of two
active site glutamate residues, Glu-52 and Glu-103, and near
the ␥-carboxylate of the glutamate substrate (Fig. 2B). A fourth
glutamate, Glu-96, and an ordered water molecule, positioned
by Glu-50, are also located adjacent to the bound magnesium
ion (2.6 Å and 2.4 Å, respectively). A water molecule occupies
the final coordination site (1.9 Å), but its corresponding electron density is poorly defined. As discussed below, binding of
ADP is accompanied by the formation of two additional magnesium binding sites.
Identification of the ADP Binding Site and Examination of the
Metal Coordination—Since convincing electron density was
not observed for the non-hydrolyzable ATP analogue in the
active site of the initial ScGCL/Glu/Mg2⫹ complex, a second
data set was collected in which ADP replaced AMP-PNP (Table
1). In the ScGCL/Glu/Mg2⫹/ADP complex, ADP is largely solvent-exposed, with its adenine ring on the outer edge of the
active site pocket, and its ␤-phosphate positioned near the
␥-carboxylate of the bound glutamate substrate. Relatively few
hydrogen bonds anchor the adenosine portion of the molecule
(Fig. 3A). The N6 atom of the adenine ring is within hydrogen
bond distance of the side chain of Gln-272. The 2⬘-hydroxyl
group of the ribose ring interacts with the backbone carbonyl of
Pro-106 via a bridging water molecule, and the 3⬘-hydroxyl
group is within hydrogen bond distance of the backbone carbonyl of Asp-49. In addition, the 3⬘-hydroxyl group forms a
hydrogen bond with a structurally conserved water molecule
that is held in place by hydrogen bonds to the backbone carbonyl of Gly-48 and the side chains of Thr-270 and Glu-50.
Lys-451, via bridging water molecules, appears to contribute to
the orientation of the ␤-phosphate. However, the most striking
interactions of this terminal phosphate are with two bound
magnesium ions, M2 and M3 (Fig. 3).
JOURNAL OF BIOLOGICAL CHEMISTRY
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To confirm the placement of the
three Mg2⫹ in the final ScGCL/Glu/
Mg2⫹/ADP complex model, a comparable data set in which the Mg2⫹
was replaced with Mn2⫹ during
crystallization was collected (Table
1). Mn2⫹ has been shown to support
catalysis by glutamate cysteine
ligase (40) and has a significant
anomalous signal at a wavelength of
1.54 Å (K edge at 1.89 Å). An anomalous difference map was calculated
and examined (Fig. 3B). Three
major peaks (⬎8) were identified,
presumably corresponding to each
of the three bound Mn2⫹ ions,
which superimpose well on the
three bound Mg2⫹ in the final
ScGCL/Mg2⫹/ADP/Glu complex
model. The interatomic Mg2⫹ distances are 4.75 Å between M1 and
M2, 4.06 Å between M2 and M3,
and 3.36 Å between M1 and M3.
Homology Modeling of the Human
Glutamate Cysteine Ligase Catalytic
Subunit (hGCLC)—There have been
several published attempts to generate a homology model of hGCLC
using either the functionally related
T. thermophilus glutamyl-tRNA synthetase or E. coli YbdK (41, 42). However, comparison of these models
FIGURE 2. Stereodiagrams of the glutamate and Mg2ⴙ binding sites. The refined model of ScGCL in com- with the ScGCL structure reported
plex with glutamate and Mg2⫹ is depicted with pertinent active site residues shown in stick representation. herein shows significant structural
Oxygen atoms are shown in red, nitrogen atoms in blue, sulfur atoms in yellow, and Mg2⫹ in purple. Carbon
atoms are colored green in ScGCL and gray in the bound glutamate (shown in ball and stick representation). dissimilarities, revealing the limitaPanel A, potential hydrogen bonds between the bound glutamate substrate and ScGCL are indicated as solid tions of models derived from such
black lines. Of particular interest is the proximity of the side chain of Cys-266 to the ␣-carboxylate of the bound
glutamate. Panel B, the coordination of the bound M1 Mg2⫹ is illustrated with relevant interatomic distances distant homologues. Using the PDBindicated (solid lines). A potential hydrogen bond between a bound water molecule and the side chain of Viewer software package (43), a
Glu-50 is designated by a dashed line.
homology model of hGCLC was generated (Fig. 4) that retains the overall
Three bound metal ions were identified in the ScGCL/Glu/ fold of ScGCL. Several regions of the hGCLC sequence (residues
Mg2⫹/ADP complex. The first metal binding site, M1, is com- 210 –223, 312–324, 490 –507) have low sequence identity to
parable to the Mg2⫹ site identified in the initial ScGCL/Glu/ ScGCL. These regions correspond to poorly defined surface loops
Mg2⫹ complex. As before, the ␥-carboxylates of Glu-52, Glu- (shown in green) in the final hGCLC model. Comparison of the
103, and the glutamate substrate are within 2.2 Å of the metal. active sites of the hGCLC homology model and the ScGCL strucThe side chain carboxylate of Glu-96 moves ⬃0.4 Å closer to ture indicates that the two enzymes have nearly identical active site
the M1 metal site, and is also positioned ⬃2.2 Å from the bound architectures with almost complete conservation of side chain
Mg2⫹. The two bound water molecules seen in the ScGCL/Glu/ functionality. A remarkable feature of the hGCLC model is that
Mg2⫹ complex are absent in the ScGCL/Glu/Mg2⫹/ADP com- the fourteen cysteine residues of the protein are located primarily
plex. The binding of ADP results in the formation of two addi- in a single hemisphere of the protein. Several of these solventtional Mg2⫹ sites. The second site, M2, is created by the side exposed cysteine residues may be important for the post-translachain oxygen atoms of Gln-268, Glu-470, and Glu-50 as well as tional regulation of hGCL activity. Atomic coordinates and strucan oxygen atom from the ␤-phosphate of ADP. Similarly, the ture factors have been deposited in the PDB under accession codes
third Mg2⫹, M3, is coordinated by side chain oxygen atoms of 3IG5 and 3IG8.
Glu-103 and Glu-50 as well as an oxygen atom from the ␤-phosphate of ADP. The ␥-phosphate of ATP would likely bind adja- DISCUSSION
cent to the ␥-carboxylate of the glutamate substrate, positioned
optimally for catalysis by the three bound Mg2⫹ ions.
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A unique feature of the ScGCL
active site is the placement of a cysteine residue, Cys-266, proximal to
the ␣-carboxylate of the glutamate
substrate (Fig. 4). This residue is
highly conserved among higher
eukaryotic GCL and its importance
has been examined in a number of
homologues (45, 46). Previous modeling studies of human GCL indicated that Cys-249, analogous to
Cys-266 of ScGCL, was located in
the periphery of the enzyme active
site and not directly involved in substrate binding or catalysis (41).
However, our model of hGCLC suggests that Cys-249 is located at the
base of the glutamate-binding
pocket. Further support for an
active role is provided by mutational
analysis of hGCLC in which
Cys-249 was substituted with a glycine, resulting in a 10-fold reduction
in enzymatic activity (47). Similarly,
a C248A/C249A double mutant in
the mouse GCL catalytic subunit
resulted in a ⬎4-fold reduction in
enzymatic activity (48). Mutagenesis studies to examine the precise
role of Cys-266 in ScGCL function
FIGURE 3. Stereodiagrams of the ADP and Mg2ⴙ binding sites. The refined model of ScGCL in complex with using both in vitro and in vivo
ADP, glutamate, and Mg2⫹ is depicted with pertinent active site residues in stick representation. Bound ligands approaches are ongoing.
are shown in ball and stick representation, and atoms are colored as in Fig. 2, with the addition of phosphorus,
Despite its inclusion in crystallishown in orange. Panel A, shown are the calculated electron density maps after several rounds of refinement,
but prior to inclusion of ADP in the model. The relevant 2Fo–Fc electron density is contoured at 1.0  and zation trials, cysteine was not
illustrated in gray. Positive and negative peaks in the Fo–Fc difference map, contoured at 4.0, are shown in blue
and red, respectively. Potential hydrogen bonds between ADP and ScGCL are indicated as solid black lines. The observed in either ScGCL complex.
adenine ring is located at the top of the active site cavity, near the surface of the protein. The ␤-phosphate is Examination of the ScGCL strucpositioned in part through interactions with Lys-451 via bridging water molecules. Panel B, the anomalous ture suggests a possible cysteine
difference map calculated using diffraction data from the corresponding Mn2⫹ complex supports the location
of each of the three bound Mg2⫹ ions in the final ScGCL model. The relevant anomalous difference peaks are binding site adjacent to the bound
contoured at 3.0  (gray) and 6.0  (red). The coordination of each of the three Mg2⫹ ions is shown as solid black glutamate substrate. Glu-96 likely
lines that correspond to atom/metal pairs with interatomic distances of ⬃2.2 Å.
forms a hydrogen bond with the
thesis and is an essential enzyme in mammalian systems (17). ␣-amino group of the incoming cysteine residue. The side
Strikingly, the ScGCL structure maintains the overall fold chains of Trp-445 and Arg-196 both point into the putative
observed in the E. coli (Group 1) (25) and the B. juncea (Group 3) L-cysteine binding site, and either residue may form a hydrogen
(26) enzymes (Fig. 1), suggesting that the three classes of enzymes bond with the ␣-carboxylate of L-cysteine. A hydrophobic
arose from a common ancestor. Conservation of side chain func- pocket, lined by Tyr-97, Phe-197, Leu-200, Met-258, and Mettionality is observed within each active site even though the three 262, could accommodate the sulfhydryl group. Additional studenzymes share ⬍10% sequence identity. For example, the M2 ies of ScGCL are required to ascertain the precise recognition
binding site of ScGCL formed by Glu-50, Gln-268, and Glu-470 mechanisms critical for cysteine binding.
(Fig. 3B) is similarly comprised of Glu27, His-150, and Glu-328 in
Conflicting catalytic mechanisms have been postulated for
the E. coli enzyme. This proposed active site conservation is fur- GCL. Early studies using the rat homologue suggested a quaterther supported by mutagenesis studies of GCL from other species. nary complex in which ATP/Mg2⫹ binds first, followed by
Arg-313 in ScGCL forms hydrogen bonds with the ␣-carboxylate L-glutamate and L-cysteine in random order (20, 49). Recent
of the glutamate substrate. In Trypanosoma brucei GCL, mutation comprehensive reports support a random ter-reactant mechaof the equivalent residue, Arg-366, to Ala increased its Kd for glu- nism in the T. brucei and Arabidopsis thaliana enzymes (46,
tamate ⬎160-fold (44). Similarly, mutation of Arg-491 (Arg-472 in 50). Examination of the reported ScGCL structures suggests
ScGCL; Fig. 2B) affected Km for glutamate modestly but decreased that the active site is large enough to accommodate ATP, Mg2⫹,
enzymatic activity of T. brucei GCL 70-fold (44), suggesting a glutamate, and cysteine simultaneously. However, the glutadirect role in catalysis.
mate-binding pocket would be completely obstructed if ATP/
NOVEMBER 20, 2009 • VOLUME 284 • NUMBER 47
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FIGURE 4. Homology modeling of human glutamate cysteine ligase. The
folded structure of hGCLC was modeled with PDBViewer software package
using the determined ScGCL structure. Panel A, the overall structure of hGCLC
is shown in ribbon representation with ␤-strands colored in yellow, ␣-helices
in blue, and loop regions in gray. Areas with low sequence identity to ScGCL
are highlighted in green and represent regions of low model confidence. Cysteine residues are shown in ball and stick representation and amino acid residues with associated clinical mutations are colored in red. For reference, ATP
was also docked within the model. Panel B, R127C mutation would disrupt a
critical structural salt bridge between Arg-127 and Asp-49 and negatively
impact the active site architecture. Panel C, Pro-158 is located in a loop region
on the surface of hGCLC. Substitution with a leucine residue may disorder this
loop, potentially impacting interactions with the modifier subunit. Panel D,
both His-370 and Pro-414 are in close proximately to a ␤-strand containing
Lys-412, which, based on comparison to ScGCL, is likely involved in orienting
the ␤-phosphate of ATP. The H370L mutation would likely lead to the loss of
two ordered water molecules which form hydrogen bonds that stabilize this
region of the structure. Similarly, P414L would disrupt this region of the protein and negatively impact ATP binding.
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Mg2⫹ and cysteine were already bound, arguing against a truly
random binding of substrates. The ScGCL structures are
consistent with an earlier study of bovine lenticular GCL, which
suggested that glutamate (or glutamate and Mg2⫹ at the M1
site) is the first substrate to bind (51). Detailed kinetic studies of
ScGCL to establish its precise mechanism are needed to resolve
these inconsistencies.
The chemical reaction catalyzed by GCL involves two distinct steps. The glutamate ␥-carboxylate, which is coordinated
to the M1 Mg2⫹, is oriented for an in-line attack of the ␥-phosphate of ATP (52), which is positioned optimally by the three
bound Mg2⫹ ions (Fig. 3B) as well as Lys-451 (Fig. 3A). The
resulting ␥-glutamylphosphate intermediate is susceptible to
nucleophilic attack by the ␣-amino group of L-cysteine (20, 49),
which may be activated by Glu-96 (40). Furthermore, structural
data and mutagenesis studies support a role for a conserved
arginine residue, Arg-472, in peptide bond formation, which
may stabilize the developing negative charge on the tetrahedral
transition state (44). Binding of the M1 Mg2⫹, which contributes to the glutamate substrate site, is ATP-independent,
whereas binding of the M2 and M3 Mg2⫹ ions requires the
presence of ATP, consistent with previous mutagenesis studies
of T. brucei GCL (40).
Homology modeling of the catalytic subunit of hGCL highlights cysteine residues that may be important for post-translational regulation. hGCL is a heterodimer comprised of a catalytic subunit that catalyzes formation of ␥-glutamylcysteine
and a modifier subunit, that increases the overall rate of product formation (30, 53). The heterodimer is stabilized by an
intersubunit disulfide bond that may couple glutathione biosynthesis with the redox state of the cell (30, 54). However,
recent work with mouse and Drosophila homologues suggests
that an intermolecular disulfide bond is not required for complex formation and allosteric activation (48, 55).
Mutagenesis studies of hGCLC cysteine residues showed
that one of its 14 cysteines (Cys-553) affects enzymatic activity
(47). However, the subunits were still able to form the heterodimer, suggesting that noncovalent interactions are also
important for holoenzyme formation. Examination of the
hGCLC model indicates that Cys-553 is located in a surface
exposed loop and may be involved in intersubunit interactions.
Three additional cysteine residues, Cys-339, Cys-491, and Cys501, map to similar mobile surface loops of the hGCLC model
(Fig. 4A). The loop containing residues 490 –507 is absent in the
monomeric ScGCL, suggesting it may be a site of interaction
with the human modifier subunit. Systematic studies are
required to directly test the significance of each of these cysteine residues with respect to intersubunit interactions.
Hereditary disorder of hGCL is a rare autosomal recessive
disease reported in 8 unrelated cases (15, 41, 42, 56 –58), and is
associated with low glutathione level in erythrocytes, markedly
decreased GCL activity, hemolytic anemia, jaundice, and in
some cases, progressive neurological disorders. Four single
nucleotide mutations have been reported in hGCL deficiency,
each leading to amino acid substitutions within the catalytic
subunit of the enzyme: R127C, P158L, H370L, and P414L (15,
41, 42, 57). Shown in Fig. 4 are the locations of each of these four
mutations in the hGCLC model. Although none are located
VOLUME 284 • NUMBER 47 • NOVEMBER 20, 2009
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directly in the enzyme active site, these residues, as well as proximal residues, are highly conserved in higher eukaryotic GCL,
including ScGCL. The exception is Pro-158. Analysis of the
ScGCL structures and the hGCLC homology model suggests
the molecular details of diminished catalytic activity.
Mutation of Arg-127 to a cysteine residue (Fig. 4B) would
disrupt a salt bridge with Asp-49 and negatively impact the
active site architecture. The backbone carbonyls of Asp-49 and
Gly-48 contribute to the ATP binding site (similar to ScGCL in
Fig. 3A) and Glu-50 is a critical catalytic residue. In addition, the
Arg-127—Asp-49 salt bridge is adjacent to a loop containing
Thr-105 and Pro-106 (Fig. 4B), which also contributes to formation of the ATP binding site. Thus, the introduction of disorder in this region by this substitution would negatively
impact catalytic efficiency.
Pro-158 is located in a surface exposed loop found in both
human GCLC and ScGCL, far removed from the enzyme
active site (Fig. 4C). This region exhibits poor sequence conservation, with an isoleucine residue, Ile-170, at the equivalent position in ScGCL. As such, it is difficult to fully explain
the phenotype associated with the P158L substitution. Perhaps the loop containing Pro-158 is involved in binding of
the regulatory subunit in the heterodimeric human enzyme.
However, other regions are also likely involved, since the
modifier subunit can still interact with the P158L mutant
(48). Interestingly, Ile-170 in ScGCL is in close proximity to
Cys-70, a potential site of oxidation (supplemental Fig. S2),
suggesting that this region may generally be involved in posttranslational regulation.
Inspection of the human GCLC model suggests that both
the H370L and P414L mutations are structurally disruptive
(Fig. 4D). His-370 forms hydrogen bonds with two bound
water molecules, which are needed to stabilize the ␤-strand
containing Lys-412. Similarly, Pro-414 is located in a fourproline stretch in the loop immediately following this same
␤-strand. The reduced enzymatic activity observed in these
two mutants is likely the result of impaired ATP binding, as
Lys-412 is equivalent to Lys-451 in ScGCL (Fig. 3A). In
ScGCL, this lysine interacts via bridging water molecules
with the ␤-phosphate of bound ADP. Further kinetic characterizations of the point mutants to confirm this assertion
are needed as previous studies did not report Km(ATP) values
for either enzyme (15, 42).
In summary, the reported complexes of ScGCL provide
considerable insight into substrate recognition, the role of
Mg2⫹ in the enzyme-catalyzed reaction, and the overall catalytic mechanism. The prominent locations of several conserved cysteine residues indicate that post-translational
modifications may be important in the regulation of enzymatic activity. Furthermore, the ScGCL structures allowed
for the generation of a reasonable homology model of the
human enzyme. Analysis of the ScGCL structures and
hGCLC model explains the molecular basis of glutathione
deficiency, resulting from clinically observed mutations in
this enzyme. Furthermore, the results of these studies may
assist in the design of novel therapeutics that modulate
intracellular glutathione levels.
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Supplemental data.

Supplemental Figure 1. Representative experimentally phased electron density map. The positions
of 1 lead and 22 sulfur atoms were identified using the PHENIX software suite and used to calculate
initial phase information. In the stereodiagram, the resulting electron density map following density
modification is shown in grey and is contoured at 1 σ. The final ScGCL model corresponding to this
region of the map is shown in stick representation with carbon atoms colored in green, oxygen in red,
nitrogen in blue, and sulfur in yellow.

Supplemental Figure 2. Cysteine70 of ScGCL is oxidized to sulfenic acid in the ScGCL/Glu/Mg2+
complex. In the stereodiagram, the amino acid residues in close proximity to Cys70 are shown in stick
representation and atoms are colored as in Supplemental Figure 1. Also shown are the calculated electron
density maps after several rounds of refinement, but prior to inclusion of sulfenic acid oxygen in the
model. The relevant 2Fo-Fc electron density is contoured at 1.0 σ and illustrated in grey. Positive and
negative peaks in the difference map, contoured at 3.0 σ, are shown in blue and red respectively.
Potential hydrogen bonds were identified with Chimera and are indicated as solid black lines.
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